← FDA Drug Approvals (Drugs@FDA)
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
ANDA · Abbreviated New Drug Application (Generic) · Sponsor: BAXTER HLTHCARE CORP · Approved 2022-10-19
Drug application
- FDA Application #
ANDA212219- Application type
- Abbreviated New Drug Application (Generic)
- Brand name
- DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
- Generic name
- Doxorubicin Hydrochloride
- Active ingredients
- DOXORUBICIN HYDROCHLORIDE
- Dosage form
- INJECTABLE, LIPOSOMAL
- Route
- INJECTION
- Marketing status
- Prescription
- Sponsor
- BAXTER HLTHCARE CORP
- First approval
- 2022-10-19
Source
- Authoritative
- Drugs@FDA application overview
- Machine
- JSON-LD · Markdown